Adjuvant Belzutifan-Pembrolizumab Significantly Boosts DFS in Kidney Cancer

(MedPage Today) — SAN FRANCISCO — The adjuvant combination of pembrolizumab (Keytruda) and belzutifan (Welireg) significantly improved disease-free survival (DFS) in patients with clear cell renal cell carcinoma (ccRCC) after nephrectomy versus…